Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIRM: Continuous versus fixed-duration daratumumab + lenalidomide + dexamethasone in relapsed multiple myeloma
2024-511855-16-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall survival at 4 years. Planned start Nov 2024; status: authorised.
02
Drugs
daratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-511855-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511855-16-00.